MXPA05008905A - 18a-homoestra-1,3,5-(10)-trien-3-il-sulfamatos 2-sustituidos, con actividad antitumoral. - Google Patents

18a-homoestra-1,3,5-(10)-trien-3-il-sulfamatos 2-sustituidos, con actividad antitumoral.

Info

Publication number
MXPA05008905A
MXPA05008905A MXPA05008905A MXPA05008905A MXPA05008905A MX PA05008905 A MXPA05008905 A MX PA05008905A MX PA05008905 A MXPA05008905 A MX PA05008905A MX PA05008905 A MXPA05008905 A MX PA05008905A MX PA05008905 A MXPA05008905 A MX PA05008905A
Authority
MX
Mexico
Prior art keywords
hydrogen
alkyl
homoestra
antitumoral
trien
Prior art date
Application number
MXPA05008905A
Other languages
English (en)
Inventor
Regenhardt Wilko
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of MXPA05008905A publication Critical patent/MXPA05008905A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La invencion se refiere al uso de compuestos de la formula general (I), en donde los grupos R2, R14 a R17 y X tienen el siguiente significado: R2 es C1-C5-Alquilo, C1-C5-Alcoxi o un restante -O-C<SB>N</SB>FmHn, en donde n=1,2,3,4,5 o 6, m>I y m+o=2n+1. R14 y R15 de manera separada designan hidrogeno o conjuntamente un grupo metilo o un enlace complementario. R16 es hidrogeno; R17 es hidrogeno, hidroxi, C1-C5-Alquilo, C1-C5-Alcoxi o SO3NHX; X es hidrogeno, C1-C5-alquilo o C1-C5acilo. En el ciclo B y D de una estructura de esteroide, las lineas punteadas pueden representar adicionalmente hasta dos dobles enlaces. Las sales de estos compuestos se describe que con farmaceuticamente aceptables para preparar farmacos.
MXPA05008905A 2003-02-19 2004-02-19 18a-homoestra-1,3,5-(10)-trien-3-il-sulfamatos 2-sustituidos, con actividad antitumoral. MXPA05008905A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10307105A DE10307105A1 (de) 2003-02-19 2003-02-19 Antitumor wirksame 2-substituierte 18a-Homoestra-1,3,5(10)-trien-3-yl sulfamate
PCT/EP2004/001630 WO2004074308A1 (de) 2003-02-19 2004-02-19 Antitumor wirksame 2-substituierte 18a-homoestra-1,3,5(10)-trien-3-yl sulfamate

Publications (1)

Publication Number Publication Date
MXPA05008905A true MXPA05008905A (es) 2005-10-05

Family

ID=32841728

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008905A MXPA05008905A (es) 2003-02-19 2004-02-19 18a-homoestra-1,3,5-(10)-trien-3-il-sulfamatos 2-sustituidos, con actividad antitumoral.

Country Status (12)

Country Link
US (1) US20060211670A1 (es)
EP (1) EP1594884B1 (es)
JP (1) JP2006517947A (es)
CN (1) CN1751060A (es)
AT (1) ATE455122T1 (es)
AU (1) AU2004213149A1 (es)
BR (1) BRPI0407579A (es)
CA (1) CA2516185A1 (es)
DE (2) DE10307105A1 (es)
MX (1) MXPA05008905A (es)
RU (1) RU2005128829A (es)
WO (1) WO2004074308A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10307104A1 (de) * 2003-02-19 2004-09-23 Schering Ag Antitumor wirksame 2-substituierte Estra-1,3,5(10)-trien-3-yl sulfamate
DE10307103A1 (de) * 2003-02-19 2004-09-09 Schering Ag Antitumor wirksame 2-substituierte D-Homostra-1,3,5(10)-trien-3-yl sulfamate

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9118478D0 (en) * 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
GB9625334D0 (en) * 1996-12-05 1997-01-22 Imperial College Compound
US6011024A (en) * 1991-08-28 2000-01-04 Imperial College Of Science Technology & Medicine Steroid sulphatase inhibitors
DE4429397C2 (de) * 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE4447714C2 (de) * 1994-08-09 1998-02-05 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur Hormonsubstitutions-Therapie
DE19540233B4 (de) * 1995-10-19 2005-08-25 Schering Ag Sulfamat-Derivate von 1,3,5(10)-Estratrien-Derivaten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US20040127473A1 (en) * 1996-12-05 2004-07-01 Reed Michael John Compound
WO1999064013A1 (en) * 1998-06-10 1999-12-16 Sterix Limited Pharmaceutical composition with tumor necrosis factor a and 2-methoxyestrone-3-o-sulphamate for inhibition of estrone sulphatase
US6642220B1 (en) * 1996-12-05 2003-11-04 Sterix Limited Compounds that inhibit oestrone sulphatase; compositions thereof; and methods employing the same
DE19712488A1 (de) * 1997-03-25 1998-10-01 Knoell Hans Forschung Ev Steroidsulfamate, Verfahren zu ihrer Herstellung und Anwendung derselben
US6548491B2 (en) * 1997-12-24 2003-04-15 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6046186A (en) * 1997-12-24 2000-04-04 Sri International Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
DE19943708B4 (de) * 1999-09-08 2007-12-20 Bayer Schering Pharma Ag Neue C13-substituierte Estra-1,3,5(10)-trien-3-yl-sulfamate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
GB0020498D0 (en) * 2000-08-18 2000-10-11 Sterix Ltd Compound
AU2003216322A1 (en) * 2002-02-15 2003-09-09 Rigel Pharmaceuticals, Inc. Inhibitors of tubulin polymerization
DE10307104A1 (de) * 2003-02-19 2004-09-23 Schering Ag Antitumor wirksame 2-substituierte Estra-1,3,5(10)-trien-3-yl sulfamate

Also Published As

Publication number Publication date
CN1751060A (zh) 2006-03-22
DE10307105A1 (de) 2004-09-09
WO2004074308A1 (de) 2004-09-02
US20060211670A1 (en) 2006-09-21
EP1594884B1 (de) 2010-01-13
EP1594884A1 (de) 2005-11-16
ATE455122T1 (de) 2010-01-15
AU2004213149A1 (en) 2004-09-02
CA2516185A1 (en) 2004-09-02
JP2006517947A (ja) 2006-08-03
BRPI0407579A (pt) 2006-02-14
RU2005128829A (ru) 2007-03-27
DE502004010636D1 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
MY126973A (en) Derivatives of 4-aminopiperidine and their use as a medicament
NO20076319L (no) Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav
MY130668A (en) Isothiazole derivatives useful as anticancer agents
IL114003A (en) 1,4,6-Trisubstituted 1H-pyrrolo[2,3-b]pyridine and 1-H-pyrazolo[3,4-b] pyridine derivatives and pharmaceutical compositions containing them and some intermediates for their preparation
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7&#39;-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
WO1999008501A3 (en) New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
MX2009006018A (es) Derivados de quinuclidinol como antagonistas de receptores muscarinicos.
MY132073A (en) Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
HK1095138A1 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
TW200619199A (en) 3-carbamoyl-2-pyridone derivatives
YU60701A (sh) Nova triciklička jedinjenja i njihova upotreba u medicini; postupak za njihovo pripremanje i farmaceutske kompozicije koje ih sadrže
IL195891A0 (en) Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use od same in therapeutics
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
MX2010006230A (es) Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3.
MY135920A (en) New phenalkyloxy-phenyl derivatives
HUP0400682A2 (hu) 5-Hidroxitriptamin-6-ligandumként használható heterociklilalkilindol- és -azaindol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
HUP0203471A2 (hu) Trombózisellenes hatású vegyületek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
GEP20094682B (en) Tricyclic pyrazole derivatives as cannabinoid receptor modulators
MXPA05008905A (es) 18a-homoestra-1,3,5-(10)-trien-3-il-sulfamatos 2-sustituidos, con actividad antitumoral.
DE3765670D1 (de) Pyridoindolderivate, ihre verwendung als arzneimittel und diese enthaltende zubereitungen.
MXPA05008906A (es) Estra-1,3,5-(10)-trien-3-il-sulfamatos 2-sustituidos, con actividad antitumoral.
ATE444965T1 (de) Sich als therapeutische mittel eignende arylalkylindole mit affinität für den serotoninrezeptor, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
MY130757A (en) Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
AP9901559A0 (en) Tricyclic 3-keto derivatives of 6-0-methylerythromycin.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal